Open Door Salon

Open Door Salon
  • 5.0 (1)
  • Life Sciences
  • Weekly

Open Door Salon is the life sciences podcast where the people building drug development, biotech investment and healthcare innovation talk on the record. Host Lori Ellis sits down with biotech and pharma executives, investors and regulators for unscripted conversations about what it takes to get new therapies to patients. Change starts with conversation.

  1. 3d ago

    What Happens to Your Company's Secrets When You Put Them Into AI | Anne Herold Li

    Anne Herold Li, shareholder at Brownstein Hyatt Farber Schreck and managing partner of its New York office, returns to Open Door Salon to discuss what public AI tools mean for patents, proprietary data and patient privacy. She explains why proprietary research should stay out of public AI tools, why electronically anonymized data may not be anonymous enough, and what a company's AI keeps when a business spins out. She also covers whether an invention made with AI can be patented, how an AI tool's disclosure can end patentability outside the United States, whose data a company's own AI is trained on, and the one governance change she would have a biotech CEO make first. Anne Herold Li | Shareholder and Managing Partner, New York, Brownstein Hyatt Farber Schreck Anne Herold Li is a shareholder at Brownstein Hyatt Farber Schreck, where she is managing partner of the firm's New York office. A first-chair trial lawyer on a Chambers-ranked patent team, she focuses on intellectual property litigation and counseling for the life sciences industry. She joined Brownstein in 2025 from Crowell & Moring. Before becoming a lawyer she trained and worked as an epidemiologist, and she holds her law degree from Fordham University School of Law. She also teaches law students and serves on the executive committee of the William C. Conner Inn of Court. LinkedIn: https://www.linkedin.com/in/anneeliseli/ (00:00) The Copenhagen enzyme dispute and public AI tools (06:03) Anonymized data, paper and an AI that escaped its test (11:31) Small biotechs, enterprise AI licenses and spinouts (17:02) Can an invention made with AI be patented? (21:12) How an AI disclosure can end patentability (27:06) What biotech boards are missing about AI (31:00) Chat MD and patient privacy (38:01) The one governance change for a biotech CEO (41:17) Advice for scientists and students, and private AI

  2. Nov 4

    How China Became a Drug Pipeline for Big Pharma | Ying Huang & Ansbert Gadicke

    Ying Huang, former CEO of Legend Biotech and now CEO of K2 Therapeutics, and Ansbert Gadicke, founder and managing partner of MPM BioImpact, join Open Door Salon to discuss how China became a source of new drugs for the global industry. They discuss why large drug companies first doubted Legend's data from China, why assets already tested in patients in China carry less risk, why K2 is based in Singapore, and why licensing has become the norm instead of acquisition. They also cover whether the bargain era is over, what US biotech founders should build, the new rules on Chinese assets in Washington and Beijing, and the diligence and trial standards that build trust. Ying Huang, PhD | Chief Executive Officer, K2 Therapeutics Ying Huang is chief executive officer of K2 Therapeutics, a Singapore-based biotech founded in 2024 that licenses drug candidates from around the world, including China, and develops them to global standards. He was previously chief executive officer of Legend Biotech, which he joined as chief financial officer in 2019, and helped lead the development and launch of the cell therapy Carvykti with Johnson & Johnson. Before Legend he was managing director and head of biotech equity research at BofA Securities, after starting his career as a principal scientist at Schering-Plough. He holds a PhD in bio-organic chemistry from Columbia University. LinkedIn: https://www.linkedin.com/in/ying-huang-74ba092/ Ansbert Gadicke, MD | Founder and Managing Partner, MPM BioImpact Ansbert Gadicke is founder and managing partner of MPM BioImpact, the biotech venture firm he started in 1992. Trained as a physician, he did research at the German Cancer Research Center, at Harvard University and at the Whitehead Institute for Biomedical Research at MIT, and worked as a consultant at The Boston Consulting Group before founding MPM. He has been a lead investor and board member at companies including BioMarin, Pharmasset, Cullinan Therapeutics, ElevateBio, Orna Therapeutics and K2 Therapeutics. He serves on the Harvard Medical School Board of Fellows and holds an MD from Goethe University Frankfurt. LinkedIn: https://www.linkedin.com/in/ansbert-gadicke-m-d-2437b5/ (00:00) Why no one believed Legend's China data (03:53) From Legend to K2: a Singapore hub-and-spoke model (06:56) Why licensed Chinese assets lower development risk (10:41) China's biotech ecosystem, and whether India can match it (13:50) Licensing over acquisition, and the end of the bargain era (18:28) Founder expectations, and how US biotechs can compete (24:42) New rules on Chinese assets in Washington and Beijing (30:35) Diligence when a partner could become restricted (34:34) Trial deaths, FDA audits and what has to go right (39:47) What drew them to this work (43:38) The hardest challenges of their careers

  3. Oct 28

    Why Stolen Biotech Research Rarely Ends Up in Court | Theresa Campobasso & Clinton West

    Theresa Campobasso and Clinton West return to Open Door Salon. Campobasso is chief strategy officer of Reinaert and a former U.S. Marine Corps intelligence officer. West is Reinaert's president of supply chain security and logistics operations and a former CIA supply chain risk leader. They discuss the Beam Therapeutics lawsuit and the insider risk signals that could catch a case like it earlier, how a faster foreign patent office lets stolen research win the patent race, why IP theft cases rarely reach court, the due diligence investors skip, and what a breach at a venture firm exposes. Theresa Campobasso | Chief Strategy Officer, Reinaert Theresa Campobasso is chief strategy officer of Reinaert, a service-disabled, veteran-owned firm that provides security, logistics and mission support to government and commercial clients. A former U.S. Marine Corps intelligence officer, she served overseas in support of special forces in Afghanistan and later helped stand up the Defense Intelligence Agency's first Acquisition Risk Task Force. Before Reinaert she was SVP for strategic accounts at Exiger and a partner and SVP at Aardwolf Global Solutions. She is a Certified Insider Threat Program Manager and holds degrees from the University of Notre Dame and Georgetown University. LinkedIn: https://www.linkedin.com/in/theresa-campobasso-02b78b56/ Clinton West | President, Supply Chain Security and Logistics Operations, Reinaert Clinton West is president of supply chain security and logistics operations at Reinaert, a service-disabled, veteran-owned firm that provides security, logistics and mission support to government and commercial clients. He spent more than two decades at the Central Intelligence Agency, where he led the Office of Supply Chain Risk Management. Earlier he served in the U.S. Navy and at the National Reconnaissance Office. Before Reinaert he led the supply chain security practice at Aardwolf Global Solutions. He traces his interest in supply chain security to moving cargo in Somalia early in his career. LinkedIn: https://www.linkedin.com/in/clinton-west-jr/ (00:00) The Beam Therapeutics case and three insider risk signals (04:05) How a faster foreign patent office wins the race (07:10) Why IP theft cases are so hard to win in court (10:29) Sources and methods, and the diligence companies skip (14:34) When an investor withholds capital: economic statecraft (20:53) When a VC's portfolio company is breached (27:01) Congress, Treasury and Section 1260H compliance (33:56) What this career asked that they did not expect (38:10) What the career cost them

  4. Oct 14

    How Health Systems Decide Which AI to Buy | Paul Uhrig & Eddie Qureshi

    Paul Uhrig is a healthcare lawyer and digital health executive, formerly Chief Legal and Digital Health Officer at Bassett Healthcare Network and Chief Administrative, Legal and Privacy Officer at Surescripts. Eddie Qureshi is founder and CEO of Rainfall Health, an AI platform that helps hospitals manage Medicare's TEAM model. They explain what health system executives ask before they buy AI, why so many pilots never reach scale, and why only two or three priorities ever make a C-suite agenda. Then the patient side: people connecting their medical records to ChatGPT and Claude, why that data falls outside HIPAA, the consent screens nobody reads, the 30 days after surgery, and why ambient listening stuck with clinicians. (00:00) The consent form nobody reads (01:55) AI, bad actors and the threat closer to home (04:13) Cybersecurity and the 100% landing rule (07:14) What executives ask before they buy AI (09:00) Why pilots fail to scale (10:31) Pitch versus pain point (14:54) Is every health system the same? (16:56) Patients bring AI to the exam room (20:19) Patient data in consumer AI tools (23:29) HIPAA, the FTC and who educates patients (26:56) The 30 days after surgery (31:21) 85% of health systems use AI (32:02) Why ambient listening stuck (35:43) What inspired their career paths (39:01) The hardest decision or challenge

  5. Oct 7

    What Cell and Gene Therapy Investors Need to See First | Phil Vanek & David Crean

    Phil Vanek, PhD, is Chief Commercialization Officer of the International Society for Cell & Gene Therapy (ISCT), chair of the CGT Catapult Technology Advisory Board and founder of Redline Bioadvisors. David H. Crean, PhD, MBA, is founder and managing partner of Cardiff Advisory and the author of Dual Fluency. They explain what a cell and gene therapy founder has to show before an investor conversation goes anywhere: a de-risked asset, evidence the biology is real, and a manufacturing plan that is not left to the appendix. They argue for writing the target product profile first, rank capital, reimbursement and manufacturing cost, compare how the US, the UK and Europe pay for advanced therapies, and explain why deals announced at JPM start many months earlier. (00:00) What founders have to show before the conversation starts (05:12) Target product profile: write the label first (09:53) Show me the data: AI, fabricated evidence, and the three pillars ranked (14:37) Who pays: reimbursement in the US, UK and Europe (19:16) The four-legged stool and the aducanumab lesson (25:10) Should you build to be acquired? Who really picks the asset (31:40) Why JPM deals start nine months earlier (36:06) Hardening the supply chain, and why science needs capital fluency (40:56) Career lessons, and killing a program that works (46:02) Mentorship and advice for emerging founders

  6. Sep 30

    Is Your Biotech a National Security Target? | Chad Raduege

    Retired Air Force Brigadier General Chad Raduege spent 29 years in communications, IT and cyber operations, commanded the White House Communications Agency, and finished his career as Director of C4/Cyber and CIO for U.S. European Command. Today he is President of Cyber, Data & Communications at Elara Nova. He explains why he sees biopharma data as a national security matter, how ransomware differs from espionage by advanced persistent threats, and why the CEO owns cyber risk at a 40-person biotech with no CISO. He describes what an adversary could learn from a venture firm's due diligence files, how he reads the summer's incidents at Amgen, Boston Scientific and McKesson, and why the industry should build security in and share what it learns. (00:00) First to market, first breached, and meet Chad Raduege (05:36) Taking the Oval Office anywhere: the White House Communications Agency (09:45) EUCOM: Afghanistan, COVID and Russia's invasion of Ukraine (14:24) Where biopharma sits on a nation-state target list (19:17) Ransomware vs. espionage, and the 40-person biotech with no CISO (25:50) VC diligence files, accountability and crown jewels (33:14) Amgen, Boston Scientific, McKesson: an adversary mapping the industry (37:40) Build it in, don't strap it on, and the path to 29 years (43:59) Stop casting stones: ISACs and learning together

  7. Sep 23

    Why Digital Twins Won't Replace Patients | Nindhana Paranthaman & Paul Agapow

    AI arrived in drug development carrying a very large promise. Nindhana Paranthaman, Vice President of Early Clinical Development at Bicara Therapeutics, and Paul Agapow, Chief Scientific Officer at Bayezian, work on opposite sides of that promise and agree on more than the marketing would suggest. Paranthaman names the gains that actually arrived, all of them operational, and the one that did not: more drugs advancing into the clinic. Agapow explains why a trial completed inside a year is marketing, takes the digital twin apart on logical rather than technical grounds, and estimates that about a third of what the industry is building today will still be standing in five years. They close on target herding and what an investor should ask an AI-first company. (01:24) What AI actually delivered in clinical development (05:24) Whether a one-year trial is marketing spin (10:30) Digital twins, and why a twin cannot replace a patient (16:39) What survives five years, and the breakdown (18:48) Protocols, amendments and the unglamorous gold (29:29) Why biology breaks AI: discovered, not invented (36:35) Target herding and the hundredth me-too drug (39:09) Advice for VCs, family offices and private equity

  8. Sep 16

    What Gets a Biotech Pitch Funded: Mike Goguen and Christian Schubert

    Six hundred investable opportunities in a year. Five investments. Christian Schubert, Vice President and Global Head of AbbVie Ventures, walks Lori Ellis through where the other 595 fall out, and almost none of it is about pitch quality. Mike Goguen joins him from the other end of the market. He spent twenty years as a general partner at Sequoia Capital before founding Two Bear Capital in 2019, and has served on more than eighty company boards. Two investors, two entirely different mandates, one table. They cover what separates a funded biotech pitch from a passed one, what loses a pitch inside the first twenty minutes, whether warm introductions still move a founder to the front of the line, why the amount raised early was almost inversely correlated with success in Goguen's own look back at the data, and what makes a rejection useful instead of vague. (00:40) Out of 600 opportunities, five investments (02:46) The five to ten percent in the middle, where the work is (03:31) Is the problem big enough? Why biotech is not tech (07:04) Passion, resilience, and the North Star nobody else believes yet (09:58) Sequoia in 1996: should we ever do life sciences again? (11:53) The capital gap corporate venture is stepping into (14:04) What is the fastest pitch you have ever lost? (16:34) What loses a pitch in the first twenty minutes (18:07) How much diligence goes into the team, not just the founder (20:42) Social worker and fireman: what early stage leadership actually is (26:50) When a founder should step aside, and who says it out loud (28:08) Do warm introductions still move you to the front of the line? (31:05) Why raising less money early correlates with bigger outcomes (35:13) Groupthink: the biggest fallacy in venture capital (38:31) What a fundable company looks like in 2027 and 2028 (43:58) The anatomy of a useful no (49:24) The fund dynamics hiding behind a rejection (53:48) The hardest questions: a random walk into venture (56:38) Three billion lines of code in every cell (01:00:30) The choice that lingers (01:02:26) Venture capitalist, philanthropist, first responder. Pick one. Mike Goguen is Founder and Managing Partner of Two Bear Capital. https://www.linkedin.com/in/michael-goguen-23314/ Christian Schubert is Vice President and Global Head of AbbVie Ventures. https://www.linkedin.com/in/crs79/ Episode page: https://opendoorsalon.com/what-gets-a-biotech-pitch-funded/

See All (37)

About

Open Door Salon is the life sciences podcast where the people building drug development, biotech investment and healthcare innovation talk on the record. Host Lori Ellis sits down with biotech and pharma executives, investors and regulators for unscripted conversations about what it takes to get new therapies to patients. Change starts with conversation.

Information

  • Creator
    Open Door Salon
  • Years Active
    2026
  • Episodes
    37
  • Rating
    Clean
  • Copyright
    © Open Door Salon
  • Show Website
    Open Door Salon